 Pembrolizumab FDA ipilimumab metastatic melanoma disease PFS chemotherapy priority review systemic therapy Merck’s study ORR anti–PD-1 duration mg Opdivo phase II side effects paclitaxel carboplatin applications long-term survival Roger M. Perlmutter MD, PhD Bristol-Myers Squibb clash stage III IV RECIST Median follow-up toxicity fatigue cough nausea pruritus rash decreased appetite constipation arthralgia diarrhea dacarbazine temozolomide decision mutation BRAF inhibitor